ATE372774T1 - Medikament zur verabreichung von amifostin und verwandten wirkstoffen - Google Patents

Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Info

Publication number: ATE372774T1
Authority: AT; Austria
Prior art keywords: administration; amifostine; medication; related ingredients; compounds
Prior art date: 2001-02-05

Application number

AT02713473T

Other languages

English (en)

Inventor

Martin Stogniew

Original Assignee

Medimmune Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-05

Filing date

2002-02-04

Publication date

2007-09-15

2002-02-04 Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE372774T1 publication Critical patent/ATE372774T1/de

Links

JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title 1
229960001097 amifostine Drugs 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000004615 ingredient Substances 0.000 title 1
-1 aminoalkyl phosphorothioate Chemical compound 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007423 decrease Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

AT02713473T 2001-02-05 2002-02-04 Medikament zur verabreichung von amifostin und verwandten wirkstoffen ATE372774T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/775,540 US6573253B2 (en)	1997-02-12	2001-02-05	Methods for the administration of amifostine and related compounds

Publications (1)

Publication Number	Publication Date
ATE372774T1 true ATE372774T1 (de)	2007-09-15

Family

ID=25104730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02713473T ATE372774T1 (de)	2001-02-05	2002-02-04	Medikament zur verabreichung von amifostin und verwandten wirkstoffen

Country Status (9)

Country	Link
US (1)	US6573253B2 (de)
EP (1)	EP1368038B1 (de)
JP (1)	JP2005504720A (de)
AT (1)	ATE372774T1 (de)
AU (1)	AU2002245321B2 (de)
CA (1)	CA2437087A1 (de)
DE (1)	DE60222383T2 (de)
ES (1)	ES2289090T3 (de)
WO (1)	WO2002062350A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994409A (en) *	1997-12-09	1999-11-30	U.S. Bioscience, Inc.	Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
EP1328253B1 (de) *	2000-04-26	2006-03-22	Oregon Health Sciences University	Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
US7053072B2 (en) *	2001-05-11	2006-05-30	Medimmune Oncology, Inc.	Methods for the administration of amifostine and related compounds
WO2004039336A2 (en) *	2002-10-31	2004-05-13	Oregon Health & Science University	Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia
EP1809272A4 (de) *	2004-10-18	2008-01-02	Maroon Biotech Corp	Verfahren und zusammensetzungen zur behandlung von schäden durch freie radikale
US20100041929A1 (en) *	2006-11-11	2010-02-18	Robert L Bedard	Selective Hydrogenation Processes Using Functional Surface Catalyst Composition
EP2141995B1 (de) *	2007-03-27	2014-11-05	Perscitus Biosciences, LLC	Zusammensetzungen und ihre verwendungen zum schutz von zellen gegen toxische wirkungen
US20100049284A1 (en) *	2008-05-15	2010-02-25	The Catholic University Of America	Use of heat to treat biological systems exposed to damaging radiation
TWI432204B (zh) *	2011-06-03	2014-04-01	Taiwan Hopax Chems Mfg Co Ltd	對抗自由基的醫藥組合物
WO2013188016A2 (en)	2012-05-04	2013-12-19	Discovery Laboratories, Inc.	Surfactant therapy for exposure to ionizing radiation
US20160143926A1 (en)	2013-06-18	2016-05-26	Aminomedix Inc.	Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
WO2019103983A1 (en) *	2017-11-21	2019-05-31	William Marsh Rice University	Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof
WO2024211590A1 (en) *	2023-04-04	2024-10-10	Xerient Pharma Ltd.	Pharmaceutically active compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3892824A (en)	1968-12-16	1975-07-01	Southern Res Inst	S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
AU629533B2 (en)	1987-12-22	1992-10-08	U.S. Bioscience, Inc.	Improving toxicity profiles in chemotherapy
EP0409845A4 (en)	1988-02-23	1991-07-03	U.S. Bioscience	Method for protection from chemotherapeutic side effects
US5869338A (en)	1992-03-13	1999-02-09	Arch Development Corporation	Method for protection against genotoxic mutagenesis
US5567686A (en)	1992-03-13	1996-10-22	Arch Development Corporation	Method for protection against genotoxic mutagenesis
US5488042A (en)	1992-03-13	1996-01-30	Arch Development Corporation	Method for protection against genotoxic mutagenesis
SG47101A1 (en)	1992-07-31	1998-03-20	Us Bioscience	Crystalline amifostine compositions and methods for the preparation and use of same
US5424471A (en)	1992-07-31	1995-06-13	U.S. Bioscience, Inc.	Crystalline amifostine compositions and methods of the preparation and use of same
WO1994005299A1 (fr)	1992-09-04	1994-03-17	Fuji Kagaku Kogyo Kabushiki Kaisha	Compositions medicinales
ATE216425T1 (de)	1994-08-13	2002-05-15	Roche Diagnostics Gmbh	Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5846958A (en)	1995-02-17	1998-12-08	U.S. Bioscience, Inc.	Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en)	1997-02-12	2000-04-18	U.S. Bioscience, Inc.	Methods for the administration of amifostine and related compounds
US5994409A (en)	1997-12-09	1999-11-30	U.S. Bioscience, Inc.	Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6984619B1 (en)	1999-03-19	2006-01-10	Arch Development Corporation	Method for protection against tumor metastasis formation

2001
- 2001-02-05 US US09/775,540 patent/US6573253B2/en not_active Expired - Lifetime
2002
- 2002-02-04 WO PCT/US2002/002256 patent/WO2002062350A1/en not_active Ceased
- 2002-02-04 JP JP2002562357A patent/JP2005504720A/ja active Pending
- 2002-02-04 DE DE60222383T patent/DE60222383T2/de not_active Expired - Lifetime
- 2002-02-04 ES ES02713473T patent/ES2289090T3/es not_active Expired - Lifetime
- 2002-02-04 EP EP02713473A patent/EP1368038B1/de not_active Expired - Lifetime
- 2002-02-04 CA CA002437087A patent/CA2437087A1/en not_active Abandoned
- 2002-02-04 AT AT02713473T patent/ATE372774T1/de not_active IP Right Cessation
- 2002-02-04 AU AU2002245321A patent/AU2002245321B2/en not_active Expired

Also Published As

Publication number	Publication date
ES2289090T3 (es)	2008-02-01
US6573253B2 (en)	2003-06-03
EP1368038A1 (de)	2003-12-10
WO2002062350A1 (en)	2002-08-15
JP2005504720A (ja)	2005-02-17
DE60222383T2 (de)	2008-06-12
US20020035093A1 (en)	2002-03-21
DE60222383D1 (de)	2007-10-25
CA2437087A1 (en)	2002-08-15
EP1368038B1 (de)	2007-09-12
AU2002245321B2 (en)	2007-08-02

Legal Events

Date	Code	Title	Description
2008-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK2070939T3 (da)	2014-06-23	Modulatorer af farmakologiske midler
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MXPA03003960A (es)	2004-09-10	Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
ATE307608T1 (de)	2005-11-15	Kombination von doctaxel und rhumab her2 zür krebsbehandlung
CY1116464T1 (el)	2017-03-15	Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR0209365A (pt)	2004-06-08	Usos farmacêuticos de bisfosfonatos
AU2002236765A1 (en)	2002-07-30	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
IL175158A0 (en)	2006-09-05	Tocopherol-modified therapeutic drug compounds
WO2004006842A3 (en)	2004-05-27	Combinations of drugs for the treatment of neoplasms
WO2004043341A3 (en)	2004-07-15	Treatment for hemorrhagic shock
ATE372774T1 (de)	2007-09-15	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
DK1007055T3 (da)	2004-06-07	Anvendelse af amifostin
GB0020504D0 (en)	2000-10-11	Therapeutic method
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
MX2008001520A (es)	2008-04-07	Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
ATE261732T1 (de)	2004-04-15	Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
IL159770A0 (en)	2004-06-20	Calcium salts with cytotoxic activity
ATE252903T1 (de)	2003-11-15	Arzneimittel zur behandlung konvulsivischer zustände
EP1374873B8 (de)	2005-06-29	Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
TR200000728T2 (tr)	2000-09-21	Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
AU2001276323A1 (en)	2002-02-13	Use of n-oleoylethanolamine for treating psoriasis
UA29280A (uk)	2000-10-16	Спосіб лікування флегмони шлунку
DK0788355T3 (da)	2000-03-20	Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme
UA29106A (uk)	2000-10-16	Спосіб лікування вібраційної хвороби
UA41781A (uk)	2001-09-17	Спосіб лікування хворих на остеоартроз